Relative Heparin-Induced Thrombocytopenic potential of Low Molecular Weight heparins and new antithrombotic agents

Clinical and Applied Thrombosis/Hemostasis

Volumn 2, Issue 1 SUPPL., 1996, Pages

  Walenga, Jeanine M ^a   Koza, Michael J ^a   Lewis, Bruce E ^a   Pifarré, Roque ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Heparin induced thrombocytopenia; Low molecular weight heparin; Thrombin inhibitors

Indexed keywords

EID: 0002787983     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wallis DE, Lewis BE, Pifarré R, Scanlon PJ. Active surveillance for heparin-induced thrombocytopenia on thromboembolism [Abstract]. Proc American College of Chest Physicians, October 30-November 3, 1994.
2. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993;70:554-61.
3. Messmore HL, Nand S, Godwin J. Heparin-induced thrombocytopenia and platelet activation in cardiovascular surgery. In: Pifarré R, ed. Anticoagulation, hemostasis, and blood preservation in cardiovascular surgery. Philadelphia: Hanley & Belfus, 1993:185-99.
4. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68:95-6.
5. Chong BH, Pilgrim RL, Cooley MA, Chesterman CN. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 1993;81:988-93.
6. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992;67:545-9.
7. Nand S, Robinson J. Plasmapheresis in the management of heparin associated thrombocytopenia with thrombosis. Am J Hematol 1988;28:204-6.
8. Lewis BE, Rao RC, Robinson JA, et al. Early plasmapheresis reduces mortality in patients with heparin-induced thrombosis [Abstract]. Blood 1995;86(suppl 1):919a.
9. Raible M, Walenga JM, Lewis BE, Pifarré R. Plasmapheresis successfully removes heparin-platelet factor 4 antibodies from patients with heparin-induced thrombocytopenia [Abstract]. Blood 1995;86(suppl 1):906a.
10. Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991;78:2194-7.
11. Lewis BE, Leya FS, Wallis D, Grassman E. Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can J Cardiol 1994;10:559-61.
12. Raible MD, Wolf H, Leya F, et al. Post-PTCA generation of HEP-PF4 antibodies is associated with previous exposure to unfractionated heparin. Studies with the chronic administration of a LMWH [Abstract]. Blood 1995;86(suppl 1):551a.
13. Nguyen P, Droulle C, Potron G. Comparison between platelet factor 4/heparin complexes Elisa and platelet aggregation test in heparin-induced thrombocytopenia. Thromb Haemost 1995;7:804-5.
14. Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vasc Surg 1986;4:522-8.
15. Gouault-Heilmann M, Payen D, Contant G, Intrator L, Huet Y, Schaeffer A. Thrombocytopenia related to synthetic heparin analogue therapy. Thromb Haemost 1985;54:557.
16. Roussi JH, Houbouyan LL, Goguel AF. Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet 1984;1:1183.
17. Massonnet-Castel S, Pelissier E, Dreyfus G, et al. Low-molecular-weight heparin in extracorporeal circulation. Lancet 1984;1:1182-3.
18. Robitaille D, Leclerc JR, Laberge R, Sahab P, Atkinson S, Cartier R. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg 1992;103:597-9.
19. Eichinger S, Kyrle PA, Brenner B, et al. Thrombocytopenia associated with low-molecular-weight heparin. Lancet 1991; 337:1425-6.
20. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
21. Walenga JM. Factor Xa inhibition in mediating antithrombotic actions: application of a synthetic heparin pentasaccharide. Doctoral thesis, the Universite Pierre et Marie Curie, Paris VI, 1987.
22. Chamberlin JR, Lewis B, Leya F, et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using hirulog. Can J Cardiol 1995;11:511-4.
23. Pifarré R, Walenga JM, Koza MJ, Hoppensteadt D, Shankey TV. Studies on platelet activation in native blood by multi-parametric flow cytometry [Abstract]. Thromb Haemost 1995;73:1001.